Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241265962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Huizhong Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of China PLA, Beijing, China. Hauptthemen laut MEDLINE: Immunotherapy, Carcinoma, Hepatocellular, Liver Neoplasms, Alternative Splicing. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Young Elite Scientists Sponsorship Program by China Association for Science and Technology,.
Abstract (Originalsprache)
Background
Integrating immune checkpoint inhibitors with multi-target tyrosine kinase inhibitors presents an innovative and hopeful strategy in liver cancer treatment. Nonetheless, a degree of resistance to this treatment is noticeable in certain patients. Alternative splicing (AS) represents a common biological process that controls the variety of life functions via isoforms.
Purpose
Investigating how gene AS affects the effectiveness of combined immunotherapy in treating hepatocellular carcinoma (HCC).
Methods
Our retrospective examination focused on AS's effect on immune therapy effectiveness, utilizing accessible tissue sequencing and clinical records for HCC. For corroborating our results, we gathered samples of drug-resistant HCC tissue, nearby tissues, HCC tissue with high drug responsiveness, and healthy liver tissue from clinical studies.
Results
The study revealed a link between the frequency of AS occurrences, the expression levels of programmed cell death 1 ligand 1, and the resistance to tumor medications. Our study detailed the AS occurrences in HCC, leading to the creation of a risk-assessment function and a predictive model using AS data. The results of our study revealed that the risk score effectively distinguished between various immune subtypes and the effectiveness of immune therapy. Additional examination of the chosen AS occurrences uncovered their effects on both the immune microenvironment and cellular immunity. Our investigation also delved into the regulatory framework of AS, uncovering the role of stringently controlled splicing factors in the emergence of tumors and the modulation of the body's immune response.
Conclusions
Increased AS in HCC diminishes the efficacy of immunotherapy; conversely, more AS in peritumoral tissue elevates the likelihood of tumor immune evasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical School of China PLA, Beijing, China.
- The First Medical Centre, Chinese PLA General Hospital, Beijing, China.
- Institute of Hepatobiliary Surgery of Chinese PLAGH, Beijing, China.
- Qingdao Central Hospital, University of Health and Rehabilitation Sciences(Qingdao Central Hospital) Qingdao, China.
- Key Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, China.
- General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Huizhong Shi
Förderung
- Young Elite Scientists Sponsorship Program by China Association for Science and Technology,
Zitieren
APA
Shi, H., Liu, Y., Liu, Z., Ge, X., Wu, J., Tang, H., Zhang, Y., & Lu, S. (2024). Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241265962
Vancouver
Shi H, Liu Y, Liu Z, Ge X, Wu J, Tang H, et al. Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241265962
BibTeX
@article{Shi2024,
author = {Shi, Huizhong and Liu, Yang and Liu, Zhao and Ge, Xinlan and Wu, Jushan and Tang, Haowen and Zhang, Yi and Lu, Shichun},
title = {Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241265962}
}
EUVIMED